08:00 - 16:00 EST | 05:00 - 13:00 PST

* Please note that the following agenda timings are Eastern Standard Time.  

For Pacific Standard Times, please download the full event guide here

8:00 am Virtual Networking

Synopsis

A chance for those coffee table conversations. Randomized 1-2-1 meetings with your peers to grow your network.

Improving the Therapeutic Window of Cell Engagers – Addressing Toxicity, Half-Life and CRS

8:30 am Chair’s Opening Remarks

  • Divya Mathur Director of Immuno-oncology, Regeneron Pharmaceuticals

8:40 am Optimizing T-cell Bispecifics in the Treatment of Solid Tumors

Synopsis

  • Pfizer has several T-cell retargeting bispecific platforms currently in the clinical development
  • Reviewing the challenges and opportunities of Pfizer T-cell retargeting bispecific platforms in context of liquid and solid tumors
  • Evaluating factors that influence potency and safety of these molecules
  • Discussing Pfizer’s bispecific discovery and optimization platform and how it’s been used for the development of T-cell retargeting bispecifics against gastrointestinal tumors

9:05 am Generation of Bispecific & Trispecific T-Cell & NK Cell- Engagers From Any IgG Without Prior Reengineering

Synopsis

• Clinical-stage GlycoConnect™ technology highly suitable to generate immune cell engagers by selective attachment of scFv or cytokines (with concomitant Fc-silencing)
• Molecular antibody architecture can be tailored to 2 : 2 or 2 : 1 ratio (CDR : scFv/cytokine), or even further combinations thereof (2 : 1 : 1)
• Functional studies corroborate the biological activity of GlycoConnect™ bispecifics and trispecifics, in terms of binding, immune cell engagement and cell-killing potential

9:30 am Live Q&A – Ask our Speakers Your Burning Questions

9:40 am Improving the Therapeutic Index with Guided Antibody Tumor Engagers (GATETM)

Synopsis

• The goal of the Revitope’s two-component bi-specific GATETM platform is to address the key liabilities of traditional T cell engagers, namely off-target and on-target/off-tumor toxicities
• The Revitope GATETM platform incorporates several design features to focus T cell redirection to the tumor
• Key design features include requirements for dual antigen expression in the tumor, tumor protease driven cleavage and activation, and a built in PK switch to limit systemic exposure of GATETM once activated in the tumor

10:05 am Protease Dependent COBRA Activity Regresses Established Solid Tumors in Mice

  • Danielle Dettling Senior Director, Pre- Clinical Pharmacology, Maverick Therapeutics

Synopsis

• Pre-clinical characterization of initial COBRA lead, MVC-101: EGFR COBRA
• Pre-clinical characterization of 2nd COBRA lead MVC-280: B7H3 COBRA
• COBRA design increases the therapeutic index over an inherently active T cell engager in tumor-bearing mice

10:30 am Simultaneous Assessment Of Efficacy And Toxicity In Humanized Mice

  • James Keck Senior Director, Innovation and Product Development , The Jackson Laboratory

Synopsis

  • A fast, reliable and reproducible model for assessing bispecific antibodies
  • Assay is 6-10 days from beginning to end
  • Able to capture cytokine release, efficacy, immunophenotyping and possible animal health and organ toxicities all in the same mouse

11:00 am Live Q&A – Ask our Speakers Your Burning Questions

  • Patricia Giblin VP of Biology, Revitope Oncology
  • Danielle Dettling Senior Director, Pre- Clinical Pharmacology, Maverick Therapeutics
  • James Keck Senior Director, Innovation and Product Development , The Jackson Laboratory

11:15 am Networking Break

11:35 am Panel Discussion: Risk Mitigation Measures & Dosing Strategy for Cell Engager Drug Candidates

Synopsis

• Strategies to identify and mitigate risks for first in–human studies
• Predict safety issues with novel cell engager design
• Ensure there are risk mitigation measures for cytokine release syndrome in study protocols
• Explore dosing strategies to maximize safety and therapeutic potential of cell engager drug candidates in hematological and solid tumor indications

12:35 pm Virtual Networking Lunch

1:35 pm Improving the Therapeutic Window of T-Cell Engagers

  • Bruce Keyt Chief Scientific Officer, IGM Biosciences

Synopsis

• IGM-2323 update on bispecific CD20xCD3

Overcoming the Tumor Microenvironment

2:00 pm Safety & Efficacy of T-Cell Engagers with Low Agonist Activity in Oncology & Infectious Diseases

Synopsis

• T-cell engagers with low agonist activity are safe and efficacious in oncology patients
• Safe T-cell engagers could potentially lead to applications outside oncology, such as chronic hepatitis B infections

2:25 pm Live Q&A – Ask our Speakers Your Burning Questions

2:35 pm Tuning the NK Cell Response to Soluble Factors in the Tumor Microenvironment

Synopsis

• 100% of NK cells within tumors express activating receptors for tumor ligands
• Several soluble factors within the tumor microenvironment can suppress NK cell cytotoxicity
• Engineering NK cell resistance to combinations of these factors leads to tumor regression

3:00 pm Macrophage Repolarization as a Key Strategy in Changing Tumor Microenvironment

Synopsis

• Tumor-associated macrophages (TAMs) are critical cells corroborating cancer progression and often preventing responses to therapies across multiple cancer type
• Verseau is utilizing its proprietary all human drug discovery and translation platform to develop a pipeline of macrophage repolarizing therapeutics
• Macrophage repolarization induces a pro-inflammatory state, that in turn activates T cells and attracts other immune cells to generate a powerful antitumor response. Given multifaceted nature of macrophage biology, we anticipate the need to direct reprogramming via highly differentiated novel molecular pathways. Data on Verseau lead monoclonal antibody programs will be presented

3:25 pm Presentation Title To Be Announced

  • Rick Austin Vice President, Research , Harpoon Therapeutics

Developing a Biomarker Strategy for Pre-Clinical and Clinical Development

3:50 pm Live Q&A – Ask our Speakers Your Burning Questions

4:00 pm ROI on Clinical Biomarkers, CDx and Precision Medicine

  • Saileta Prabhu VP/Global Head, Clinical Biomarker Innovation & Development, Takeda

Synopsis

• Streamline biomarkers in clinical development to help with decision-making
• Overcome challenges in CDx development

4:25 pm Biomarker strategies for optimal Immuno-Oncology combinations

  • Nuzhat Pathan Senior Director, Translational and Immuno-Oncology, Pfizer

Synopsis

  • Tumor intrinsic and extrinsic factors determine response to cancer therapy
  • Biomarker based tumor classification is helpful for designing therapeutic combination strategies
  • Successful biomarker driven combination strategies have been developed in multiple tumor types

4:50 pm Live Q&A – Ask our Speakers Your Burning Questions

  • Saileta Prabhu VP/Global Head, Clinical Biomarker Innovation & Development, Takeda
  • Nuzhat Pathan Senior Director, Translational and Immuno-Oncology, Pfizer

5:00 pm Chair’s Closing Remarks

5:10 pm End of Conference